PRLD's Quality Score rose 1 point on Mon, Oct 26, to 3. Buying volume reached a 20-day high.
Follow PRLD's trial news. Pro members can get an alert when Prelude Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 45% from its Aug 21, 2026 high.
2 more reasons why PRLD is down from its high, from its filings, with the other side, how the business stands, the timeline, and its peers, for Pro members.
| Holding it back | 29.5% more shares than a year ago |
| Latest filing | 10-Q, Aug 11 |
6 more reasons behind PRLD's 3, for Pro members.
After its last 4 reports it closed +8.1% on average, higher 3 of 4 times.
$152M in cash
Director David P Bonita bought 2,815,315 shares on Apr 21. 1 more insider trade this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below AverageTrending up, 5 of 14 chart checks firingWhat the Quality Score means
PRLD is #94 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 94 |
Expected to report Wed Nov 11, before the open (in 16 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“Along with the decrease in stock-based compensation expense, the decrease was primarily related to lower expense incurred for our SMARCA2 clinical trials which we paused in 2025 along with a decrease in employee related expenses due to a workforce reduction in the second half of 2025.”
PRLD's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The decrease in general and administrative expenses was primarily due to a decrease in stock-based compensation along with a decrease in employee-related expenses.”
From its results filing (SEC filing · Aug 11)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 11, 2026 | +2.5% | +10.1% | +16.6% |
| May 12, 2026 | 0.0% | -3.3% | -9.6% |
| Mar 10, 2026 | -3.2% | +16.5% | +8.7% |
In ETFs: PRLD is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
“We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of precision oncology therapies optimized to target the key driver mechanisms in cancers with high unmet need.”
PRLD scores 3 today, which Breakaway calls Below Average. It is #94 of 291 in Biotech by Quality Score, with 5 of 14 chart checks firing. Down 45% from its Aug 21, 2026 high. Shares: 29.5% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PRLD scores 3 today, which Breakaway calls Below Average (0 to 5). That is #94 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PRLD's 3.
Expected to report Wed Nov 11, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. PRLD closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.